Literature DB >> 8074011

Abnormal coronary flow velocity pattern in patients with left ventricular hypertrophy, angina pectoris, and normal coronary arteries: a transesophageal Doppler echocardiographic study.

K Isaaz1, J F Bruntz, D Paris, G Ethevenot, E Aliot.   

Abstract

Previous invasive studies have suggested that coronary flow reserve is impaired in patients with left ventricular hypertrophy (LVH) and symptoms of ischemia. We tested whether transesophageal Doppler, a semiinvasive technique, can detect altered characteristics of baseline coronary blood flow velocity in such patients. Thirty patients with LVH (hypertrophic cardiomyopathy in 4, aortic stenosis in 17, hypertension in 9) were studied. Fourteen patients had asymptomatic LVH. Sixteen patients had clinical symptoms of ischemia with angiographically normal epicardial coronary arteries. Ten subjects with no cardiovascular disease were studied as a control group. Peak diastolic and systolic coronary flow velocities were recorded in the proximal part of the left anterior descending artery (LAD) with the use of pulsed Doppler guided by color flow imaging. Patients with symptomatic LVH had higher diastolic peak coronary flow velocity (81 +/- 10 cm/sec, p = 0.0001) compared with normal subjects (41 +/- 8 cm/sec) and patients with asymptomatic LVH (44 +/- 8 cm/sec). In patients with asymptomatic LVH the diastolic coronary flow velocity/indexed ventricular mass ratio was lower (0.28 +/- 0.09 cm/gm/m2, p = 0.0001) compared with symptomatic patients (0.52 +/- 0.12 cm/gm/m2) and compared with controls (0.47 +/- 0.16 cm/gm/m2). Patients with symptomatic LVH but no aortic stenosis also had higher peak systolic coronary flow velocity (38 +/- 9 cm/sec) compared with the other groups (p = 0.0001). In the group of patients with aortic stenosis a significant inverse linear relation was found between peak systolic coronary flow velocity and peak pressure gradient (r = -0.60, p 0.01). In conclusion, patients with symptomatic LVH have abnormally high baseline coronary flow velocities resulting in magnified intimal shear stress. Because flow velocity equals flow/vessel cross-sectional area, it is suggested that high coronary flow velocities in patients with symptomatic LVH result from both augmented coronary flow and failure of the vessel to enlarge commensurately with the increase in LV mass (relative functional stenosis). In patients with aortic stenosis, peak systolic coronary flow velocity appears to be influenced by transvalvular pressure drop.

Entities:  

Mesh:

Year:  1994        PMID: 8074011     DOI: 10.1016/0002-8703(94)90623-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy.

Authors:  J J Crowley; P S Dardas; A A Harcombe; L M Shapiro
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

2.  Aortic stenosis and angina with normal coronary arteries: the role of coronary flow abnormalities.

Authors:  T Irvine; A Kenny
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

Review 3.  [Methods for coronary functional assessment].

Authors:  M Elsner
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

4.  Coronary flow reserve and exercise capacity in hypertrophic cardiomyopathy.

Authors:  P P Dimitrow; M Krzanowski; W Bodzoń; A Szczeklik; J S Dubiel
Journal:  Heart Vessels       Date:  1996       Impact factor: 2.037

5.  Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  P Petkow Dimitrow; M Krzanowski; R Nizankowski; A Szczeklik; J S Dubiel
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

Review 6.  Wave intensity analysis and its application to the coronary circulation.

Authors:  C J Broyd; J E Davies; J E Escaned; A Hughes; K Parker
Journal:  Glob Cardiol Sci Pract       Date:  2017-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.